Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
The dioxonapthoimidazolium YM155 is a survivin suppressant which has been investigated as an anticancer agent in clinical trials. Here, we investigated its growth inhibitory properties on a panel of immortalized and patient derived renal cell carcinoma (RCC) cell lines which were either deficient in...
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
Public Library of Science (PLoS)
2017-01-01
|
| Colección: | PLoS ONE |
| Acceso en línea: | http://europepmc.org/articles/PMC5459331?pdf=render |